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Abstract: The establishment of multiplex photoacoustic molecular imaging 
to characterize heterogeneous tissues requires the use of a tunable, thermally 
stable contrast agent targeted to specific cell types. We have developed a 
multiplex  photoacoustic  imaging  technique  which  uses  targeted  silica-
coated  gold  nanorods  to  distinguish  cell  inclusions  in  vitro.  This  paper 
describes  the  use  of  tunable  targeted  silica-coated  gold  nanorods  (SiO2-
AuNRs)  as  contrast  agents  for  photoacoustic  molecular  imaging.  SiO2-
AuNRs  with  peak  absorption  wavelengths  of  780  nm  and  830  nm  were 
targeted to cells expressing different cell receptors. Cells were incubated 
with  the  targeted  SiO2-AuNRs,  incorporated  in  a  tissue  phantom,  and 
imaged  using  multiwavelength  photoacoustic  imaging.  We  used 
photoacoustic  imaging  and  statistical  correlation  analysis  to  distinguish 
between the unique cell inclusions within the tissue phantom. 
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1. Introduction 
The development of a non-invasive multiplex molecular imaging technique capable of high 
resolution at significant tissue depths would aid in the diagnosis and monitoring of diseases 
such  as  cancer.  To  address  this  need,  we  have  developed  a  multiplex  molecular  imaging 
approach based on multispectral photoacoustic (PA) imaging of silica-coated gold nanorod 
(SiO2-AuNR)  contrast  agents  targeted  to  specific  cell  receptors.  A  multiplex  molecular 
#145782 - $15.00 USD Received 18 Apr 2011; revised 27 May 2011; accepted 31 May 2011; published 2 Jun 2011
(C) 2011 OSA 1 July 2011 / Vol. 2,  No. 7 / BIOMEDICAL OPTICS EXPRESS  1829imaging method, capable of imaging multiple distinct molecular signatures within a single 
image, is necessary for sensitive detection of molecular and cellular content of heterogeneous 
tissue that is typical in cancer. Molecular imaging methods previously developed, including 
optical tomography [1], micro-computed tomography (micro-CT) [2], nuclear imaging [3], 
and  magnetic resonance imaging (MRI) [1], have limitations  with respect to ease of use, 
safety, or cost. Ultrasound (US) imaging using contrast agents has been adapted for molecular 
imaging [4] due to the relative safety, high resolution, and affordability of the ultrasound 
technology. A complementary imaging mode, PA molecular imaging, has been demonstrated 
to be capable of imaging specific tumor cell types [5] with a sensitivity of 1.25 picomolar of 
targeted gold nanorod contrast agent [6]. 
Photoacoustic  imaging  uses  pulsed  laser  light  to  generate  ultrasound  transients  from 
optically absorbing materials through thermoelastic expansion [7]. Photoacoustic signals are 
recorded and used to construct an image of the optical properties of the tissue of interest, 
providing functional information about the tissue [8,9]. Photoacoustic signal can be enhanced 
using  contrast  agents,  such  as  metallic  nanoparticles  which  demonstrate  surface  plasmon 
resonance, providing high optical absorption of a tuned laser light followed by the generation 
of acoustic transients [10–12]. Gold nanoparticles have minimal toxicity and immunogenicity 
[13], encouraging the  study  of gold nanoparticles  for biomedical imaging applications. In 
particular, gold nanorods are ideal PA contrast agents, because their optical absorption spectra 
can be tuned over a broad wavelength range in the near infrared (NIR) spectral region to take 
advantage of both the tissue optical window and the higher laser fluences allowable by ANSI 
standards,  which are between 20 and 100 mJ/cm
2 in the NIR range [14]. Optical fluence 
decreases approximately 1 order of magnitude every 3 cm in breast tissue in the NIR [15], 
indicating laser fluences sufficient to generate PA signal from nanorod contrast agents can be 
achieved at several centimeters depth in clinically relevant tissues. However, these higher 
fluences  will  cause  gold  nanorods  to  change  their  optical  absorption  spectra  due  to  the 
nanorods inherent thermal instability, which is accelerated upon exposure to pulsed laser light. 
Gold nanorods begin to demonstrate changes in optical absorption spectra at 8 mJ/cm
2 with as 
few as 300 laser pulses [16], suggesting that in vivo PA imaging within 1 cm of the skin 
surface would cause degradation, and therefore the loss of optimal optical properties, of the 
nanorod contrast agents. For these reasons, a silica-coating method of providing improved 
stability during PA imaging [16] has been used in this work. 
The  chosen  targets  of  the  multiplex  nanoparticles,  epidermal  growth  factor  receptor 
(EGFR) and human epidermal growth factor receptor 2 (HER2), are both associated with poor 
patient prognosis in many cancers, including head and neck, ovarian, cervical, bladder and 
esophageal  cancers  [17–19].  Studying  the  combination  of  EGFR  family  of  receptors  can 
provide an improved prediction of patient prognosis [20]. In particular, HER2 is unique in that 
it is not activated by EGFR family ligands, only acting as a heterodimerization partner for the 
other EGFR family receptors. This feature makes HER2 a complementary choice for use as a 
indicator of prognosis in combination with EGFR [18]. Additionally, the cell lines chosen for 
this  study,  A431  and  MCF7,  have  known  cell  receptor  expression  patterns:  MCF7  cells 
present low expression of EGFR [21] and higher expression of HER2 [22], while A431 cells 
present high expression of EGFR [23] and low expression of HER2 [22]. 
The molecular photoacoustic imaging system demonstrated here improves upon previous 
in vitro multiplex photoacoustic imaging results [24,25] by using multiplex photothermally 
stable and tunable SiO2-AuNRs which provide enhanced PA signal [16,26] and by acquiring 
multispectral PA data [27]. These improvements are necessary for successful adaptation of the 
multiplex imaging method to in vivo animal models where the spectra of the AuNRs must be 
explicitly resolved from endogenous contrast agents. Additionally, while SiO2-AuNRs have 
increased  stability  as  contrast  agents  for  photoacoustic  imaging  [28,29],  they  also  exhibit 
significantly  enhanced  PA  signal  in  comparison  to  non-silica  coated  nanorods,  acting  as 
nanoamplifiers [26]. We also anticipate that the more rounded shape of the SiO2-AuNRs will 
be advantageous to cellular uptake, since the high aspect ratio of nanorods decreases their 
endocytosis in cells in comparison to more spherical nanoparticles. In this work we have also 
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AuNRs, demonstrated their uptake in vitro, and the subsequent generation of PA images of 
the cellular targets. Using both multispectral PA imaging and targeted SiO2-AuNR contrast 
agents,  these  methods  distinguish  between  two  different  types  of  cells  contained  within 
inclusions in a tissue-mimicking phantom. 
2. Materials and methods 
2.1. SiO2-AuNR Synthesis and Bioconjugation 
The  synthesis  of  silica-coated  gold  nanorods  occurred  through  a  multistep  process  as 
previously reported [16]. In summary, gold seeds  were synthesized from gold(III)chloride 
hydrate  in  the  presence  of  the  surfactant  cetyltrimethyl-ammonium  bromide  (CTAB)  by 
adding sodium borohydride. A nanorod growth solution was created by adding silver nitrate, 
gold(III)chloride hydrate, CTAB, and ascorbic acid to the seed solution [30]. The resulting 
nanorods  were  centrifuged  at  18,000  g  for  45  minutes  and  redispersed  in  ultrafiltered 
deionized water twice. Next, a layer of mPEG-thiol was formed on the surface of the gold 
nanorods through ligand exchange  with the CTAB, followed by growth of an amorphous 
silica layer using tetraethyl orthosilicate (TEOS) via the Stöber method [29]. Transmission 
electron microscopy (TEM) images were acquired to characterize the composition and size of 
the resulting SiO2-AuNRs. 
Directional bioconjugation of the SiO2-AuNRs was accomplished by functionalizing the 
silica-coated surface and using a heterofunctional crosslinker reported in previous procedures 
[31].  First,  the  silica  coating  of  the  nanorods  was  functionalized  using  (3-
aminopropyl)tris(trimethylsiloxy)silane. Monoclonal antibodies targeted to HER2 and EGFR 
were  conjugated  to  the  amine  functional  group  using  the  heterofunctional  crosslinker 
sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate [31]. Two distinct SiO2-
AuNRs were synthesized, the first with a peak optical absorption of 780 nm targeted to HER2, 
and the second with a peak optical absorption of 830 nm targeted to EGFR. The UV-Vis 
absorbance spectra of the two targeted SiO2-AuNRs were measured using a microplate reader 
(Biotek Synergy HT). 
2.2. Cell Culture 
For these experiments, A431 cells, which over-express EGFR, and MCF7 cells, which over-
express  HER2,  were  cultured  using  standard  techniques  in  Dulbecco’s  modified  eagle 
medium (DMEM) and incubated at 37°C with 5% CO2 at 95% relative humidity. During 
typical cell culture, media was exchanged every two days and cells were passaged when 90% 
confluent. 
2.3. In vitro SiO2-AuNR uptake 
To demonstrate effectiveness of targeting, cells were grown on glass coverslips until adherent, 
incubated  with  both  targeted  and  non-targeted  SiO2-AuNRs  dispersed  in  phenol  red-free 
DMEM, for 24 hours, and then mounted on glass slides for optical microscopy. Brightfield 
microscopy images were acquired of the cells incubated with either the targeted or the non-
targeted  SiO2-AuNRs,  which  had  a  bare  silica  surface.  To  quantify  the  uptake  of  gold 
nanorods,  cells  incubated  with  either  the  targeted  or  the  non-targeted  SiO2-AuNRs  were 
harvested, acid digested and the quantity of gold in each sample was analyzed by inductively 
coupled  plasma  mass  spectrometry  (ICP-MS).  To  calculate  the  number  of  SiO2-AuNRs 
nanoparticles  per  cell,  the  amount  of  gold  per  nanoparticle  was  calculated  based  on  the 
quantity of gold added during synthesis of the SiO2-AuNRs and the volume of gold contained 
within each SiO2-AuNR as estimated from TEM images. The cell concentration of the cell 
solution  harvested  after  incubation  with  the  SiO2-AuNRs  was  calculated  using  a 
hemocytometer, so that the quantity of gold detected by ICP-MS can then be used to calculate 
the number of nanoparticles per cell. 
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To  demonstrate  multiplex  photoacoustic  molecular  imaging  in  vitro,  a  tissue-mimicking 
phantom containing inclusions of both A431 and MCF7 cells loaded with the specifically 
targeted  SiO2-AuNRs  was  created.  Cultures  of  adhered  cells  were  incubated  with  1x10
12 
NRs/mL for 24 hours. Cells were then harvested and resuspended in phenol red-free media at 
a concentration of 1x10
6 cells/mL. The tissue phantom (8%  w/v  gelatin, 1.2%  w/v 5 µm 
diameter  silica  scatterers)  was  constructed  to  contain  20  µL  inclusions  consisting  of  the 
gelatin solution mixed 1:1 with the cell samples. 
As shown in Fig. 1, a tunable OPO system pumped by a pulsed Nd:YAG laser was used to 
irradiate and generate PA signal from the tissue phantom at several wavelengths between 700 
nm and 910 nm. A transducer (25 MHz, 60% fractional bandwidth, f/#4, 25 mm focal depth) 
was used to collect both US and PA signals. The transducer was moved using a 1D axis in 100 
µm steps, and radiofrequency (RF) signals were acquired at each step. The ten RF-signals 
acquired at each lateral position were averaged before to produce US and PA images [32]. 
 
Fig. 1. Custom-built system used to acquire combined US and PA images of cell phantom. 
Correlation between the wavelength-dependent PA signal intensity and the UV-Vis optical 
absorption spectra was performed using an intraclass correlation (ICC) [32]. A correlation 
method,  in  contrast  to  a  regression  analysis,  makes  no  assumptions  about  the  variable 
dependence.  The  ICC  was  chosen  as  an  assessment  of  the  agreement  between  different 
methods  used  on  the  same  set  of  subjects.  In  comparison  to  other  common  correlation 
methods, such as a Pearsons’ correlation, the ICC does not require the assignment of the two 
measurement methods to a particular order. A threshold of 0.75 was used to identify pixels 
which showed high correlation (0.75) or did not correlate (<0.75) to the nanoparticle UV-Vis 
absorbance spectra. 
3. Results and discussion 
As shown in Fig. 2a and Fig. 2b, the synthesized gold nanorods are uniformly coated with 
silica with an approximate thickness of 40 nm. The UV-Vis spectra of the two targeted SiO2-
AuNRs are shown in Fig. 2c and Fig. 2d. The maximum peak absorption wavelengths were 
780 nm and 830 nm. The absorption of the gold nanorods in the NIR is intended to improve 
the depth at which the nanorods could be imaged in future in vivo experiments. 
Targeting of the SiO2-AuNRs using monoclonal antibodies specific for over-expressed cell 
receptors results in an increase in the cellular uptake. Brightfield microscopy (Fig. 3a and Fig. 
3d) shows an increased amount of SiO2-AuNRs uptaken by cells incubated with the targeted 
SiO2-AuNRs, in comparison to cells incubated with the non-targeted SiO2-AuNRs (Fig. 3b 
and Fig. 3d), indicated by the areas which appear pink within the cells. The increased uptake 
of  the  targeted  SiO2-AuNRs  was  quantitatively  confirmed  by  ICP-MS.  The  number  of  
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Fig. 2. Characterization of multiplex SiO2-AuNRs. TEM images showing the size of the as-
synthesized SiO2-AuNRs (prior to bioconjugation) with peak optical absorbances of 780 nm (a) 
and 830 nm (b). UV-Vis spectra showing the peak optical absorption of the targeted SiO2-
AuNRs are shown in (c) and (d). 
 
Fig. 3. Optical microscopy images demonstrating enhanced uptake of targeted silica-coated 
gold nanorods (SiO2-AuNRs). a) SiO2-AuNRs targeted to the EGFR receptor are uptaken in 
greater amounts in A431 cells in comparison to b) non-targeted SiO2-AuNRs with an identical 
aspect ratio. Likewise, d) SiO2-AuNRs targeted to the EGFR show increased uptake in A431 
cells in comparison to e) non-targeted SiO2-AuNRs. Cells which have not been exposed to 
SiO2-AuNRs are shown in panel c) and panel f) as controls. Images obtained using a 20 × 
objective (0.5 NA) and Leica 6000 DM microscope. 
SiO2-AuNRs nanoparticles per cell was calculated to be 3x10
5 when HER2 targeted SiO2-
AuNRs were incubated with MCF7 cells (2x greater than untargeted SiO2-AuNRs), and 5x10
5 
when  EGFR  targeted  SiO2-AuNRs  were  incubated  with  A431  cells  (13x  greater  than 
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4  HER2 
receptors/cell [33], while A431 cells express approximately 2x10
6 EGFR receptors/cell [34], 
the increase in the uptake of gold in the A431 cells in comparison to the MCF7 cells seen in 
the ICP-MS results would be expected. The calculated number of nanoparticles per cell is 
similar to other results quantifying the cellular uptake of nanoparticles in vitro [32,35]. In 
vivo, directional bioconjugation of cell receptor targeting antibodies to the SiO2-AuNRs will 
increase the amount of nanoparticles uptaken and retained within a cancerous tumor [36], 
increasing the sensitivity of the PA imaging method to the molecular heterogeneity of tissue. 
An US image of the tissue phantom shows the presence of inclusions, but the inclusions 
containing SiO2-AuNRs cannot be distinguished from inclusions which do not contain SiO2-
AuNRs  (Fig.  4a).  Strong  PA  signal  intensities  identify  the  presence  of  nanorods  in  the 
expected inclusions, while the control inclusions that have no photoabsorbers exhibit no PA 
signal  (Fig.  4b).  However,  since  nanorods  of  differing  optical  absorption  spectra  –  the 
multiplex  SiO2-AuNRs  -  were  used  to  target  different  cell  types,  the  cell  types  can  be 
identified using the multispectral PA imaging signals. An agreement between the UV-Vis 
spectra of the SiO2-AuNRs and the wavelength-dependent PA signal intensity of each cell 
inclusion can be seen (Fig. 4c). An intraclass correlation (ICC) between the multi-wavelength 
PA signal and the optical absorption spectra of SiO2-AuNRs measured by UV-Vis allows for 
the distinction between the two different cell types within the tissue phantom (Fig. 4d). In this 
image,  ICC  values  greater  than  0.75  correlating  the  PA  signal  intensity  and  the  UV-Vis 
spectra of the λmax = 830 nm SiO2-AuNRs are plotted in red, while ICC values greater than 
0.75 correlating the PA signal intensity and the UV-Vis spectra of the λmax = 780 nm SiO2-
AuNRs  are  plotted  in  yellow,  clearly  defining  the  locations  and  boundaries  of  the  cell 
inclusions. In this case, we have used SiO2-AuNRs with peak optical absorption wavelengths 
separated only by 50 nm. However, due to the width of the optical absorption peak, we were 
unable  to  identify  the  presence  of  both  nanorods  mixed  within  a  single  inclusion. 
Improvements  in  the  synthesis  of  homogeneous  nanorods  with  very  narrow  UV-Vis 
absorption bands will permit the distinction between nanorods which are less than 50 nm apart 
in their peak optical absorption wavelength. 
 
Fig.  4.  Signal processing  and  statistical  analysis  of  the  PA  images  acquired  from  the  cell 
phantoms demonstrates the unique identification of the cell inclusions. a) The inclusions can be 
seen in the ultrasound image. b) The PA image, acquired at 830 nm, indicates which inclusions 
contain SiO2-AuNRs. c) Comparison of PA signal intensity (points) and UV-VIS spectra (solid 
lines) demonstrates that the SiO2-AuNRs optical absorption spectra determine the PA signal 
intensity. Inclusions were segmented into three areas and the PA signal intensity was averaged; 
error bars represent one standard deviation (n = 3). d) Molecular map of cells and US overlay; 
830 nm SiO2-AuNRs are shown in red, 780 nm SiO2-AuNRs are shown in yellow (ICC > 
0.75). FOV = 3.5 mm x 53 mm, US image dynamic range = 35 dB, PA image dynamic range = 
10 dB. 
4. Conclusions 
Using photothermally stable SiO2-AuNR, which have enhanced PA signal in comparison to 
PEGylated AuNRs, and a multispectral PA imaging methodology, our studies demonstrate an 
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(C) 2011 OSA 1 July 2011 / Vol. 2,  No. 7 / BIOMEDICAL OPTICS EXPRESS  1834approach which can be used to identify multiple cell types within heterogeneous tissue. By 
analyzing the PA signal intensity as a function of laser wavelength, we correlate the PA signal 
to the optical absorption spectra of the SiO2-AuNR contrast agents. Since two different SiO2-
AuNR contrast agents were used to label each unique cell type, we can identify the location of 
the specific cell types and generate a molecular image of the tissue phantom. These improved 
multiplex PA imaging methods, which are demonstrated in vitro in this work, will enable the 
implementation of multiplex PA imaging in vivo. 
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